Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,647 | 87 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $320.32 | 16 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $202.41 | 10 | $0 (2024) |
| PFIZER INC. | $141.95 | 8 | $0 (2024) |
| Janssen Biotech, Inc. | $127.87 | 8 | $0 (2023) |
| Regeneron Healthcare Solutions, Inc. | $102.72 | 4 | $0 (2024) |
| GENZYME CORPORATION | $101.94 | 4 | $0 (2024) |
| Celgene Corporation | $95.99 | 6 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $62.92 | 4 | $0 (2024) |
| Ipsen Biopharmaceuticals, Inc | $60.17 | 3 | $0 (2024) |
| Merck Sharp & Dohme LLC | $54.72 | 4 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $687.84 | 34 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($141.30) |
| 2023 | $373.84 | 21 | Janssen Biotech, Inc. ($62.80) |
| 2022 | $228.54 | 12 | ABBVIE INC. ($89.51) |
| 2021 | $124.29 | 7 | AbbVie Inc. ($56.15) |
| 2020 | $107.72 | 6 | AbbVie Inc. ($64.26) |
| 2019 | $124.46 | 7 | AbbVie, Inc. ($58.12) |
All Payment Transactions
87 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $23.52 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/12/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $23.15 | General |
| Category: VIROLOGY | ||||||
| 12/11/2024 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | Cash or cash equivalent | $28.12 | General |
| Category: THERAPY FOR CSID | ||||||
| 12/03/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $18.43 | General |
| Category: Gastroenterology | ||||||
| 11/18/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $20.23 | General |
| Category: Rare Disease | ||||||
| 11/13/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $28.06 | General |
| Category: Immunology | ||||||
| 10/29/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $16.11 | General |
| Category: Gastroenterology | ||||||
| 10/01/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $20.91 | General |
| Category: Gastroenterology | ||||||
| 09/30/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $22.29 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/23/2024 | PFIZER INC. | VELSIPITY (Drug) | Food and Beverage | In-kind items and services | $18.28 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 07/29/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $28.62 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 07/25/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $15.74 | General |
| Category: Neuroscience | ||||||
| 07/15/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $19.57 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 06/26/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $23.80 | General |
| Category: Gastroenterology | ||||||
| 06/13/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $15.84 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 06/06/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $28.88 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 05/17/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $19.39 | General |
| Category: Immunology | ||||||
| 05/15/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $22.79 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 05/13/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $20.36 | General |
| Category: Gastroenterology | ||||||
| 05/08/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $23.32 | General |
| Category: Immunology | ||||||
| 05/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $14.15 | General |
| Category: Neuroscience | ||||||
| 04/17/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $21.98 | General |
| Category: Gastroenterology | ||||||
| 04/15/2024 | Ipsen Biopharmaceuticals, Inc | Bylvay (Drug) | Food and Beverage | In-kind items and services | $14.98 | General |
| Category: Gastroenterology | ||||||
| 04/10/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $14.18 | General |
| Category: Neuroscience | ||||||
| 03/18/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $19.71 | General |
| Category: Gastroenterology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 543 | 601 | $333,287 | $54,758 |
| 2022 | 15 | 536 | 572 | $319,725 | $55,294 |
| 2021 | 19 | 754 | 3,091 | $635,504 | $156,395 |
| 2020 | 23 | 774 | 3,102 | $592,395 | $166,234 |
All Medicare Procedures & Services
72 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 79 | 80 | $75,440 | $15,576 | 20.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 132 | 187 | $51,612 | $11,376 | 22.0% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 80 | 80 | $48,000 | $4,577 | 9.5% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 22 | 22 | $16,434 | $3,683 | 22.4% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 27 | 27 | $21,411 | $3,069 | 14.3% |
| 43248 | Insertion of guide wire with dilation of esophagus using a flexible endoscope | Facility | 2023 | 23 | 24 | $37,344 | $2,405 | 6.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 36 | 36 | $12,204 | $2,396 | 19.6% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 19 | 19 | $14,193 | $2,364 | 16.7% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 12 | 12 | $8,964 | $2,084 | 23.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 13 | 13 | $6,591 | $1,550 | 23.5% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 32 | 32 | $7,072 | $1,485 | 21.0% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 20 | 20 | $8,160 | $1,386 | 17.0% |
| 43249 | Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | Facility | 2023 | 12 | 12 | $16,908 | $1,213 | 7.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 24 | 25 | $4,250 | $802.87 | 18.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 12 | 12 | $4,704 | $792.27 | 16.8% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 95 | 95 | $89,585 | $18,261 | 20.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 109 | 137 | $37,812 | $8,042 | 21.3% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 30 | 30 | $22,410 | $5,211 | 23.3% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 77 | 77 | $46,200 | $4,666 | 10.1% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 27 | 28 | $20,916 | $3,674 | 17.6% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 28 | 28 | $22,204 | $2,180 | 9.8% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 12 | 12 | $8,964 | $2,121 | 23.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 19 | 19 | $9,633 | $2,028 | 21.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 35 | 35 | $11,865 | $1,663 | 14.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 11 | 11 | $6,468 | $1,662 | 25.7% |
About Dr. Michael Fry, MD
Dr. Michael Fry, MD is a Gastroenterology healthcare provider based in Gainesville, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1407943194.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Fry, MD has received a total of $1,647 in payments from pharmaceutical and medical device companies, with $687.84 received in 2024. These payments were reported across 87 transactions from 26 companies. The most common payment nature is "Food and Beverage" ($1,647).
As a Medicare-enrolled provider, Fry has provided services to 2,607 Medicare beneficiaries, totaling 7,366 services with total Medicare billing of $432,681. Data is available for 4 years (2020–2023), covering 72 distinct procedure/service records.
Practice Information
- Specialty Gastroenterology
- Other Specialties Gastroenterology
- Location Gainesville, GA
- Active Since 10/06/2006
- Last Updated 04/15/2019
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1407943194
Products in Payments
- DUPIXENT (Biological) $204.66
- XIFAXAN (Drug) $164.32
- HUMIRA (Biological) $157.09
- STELARA (Biological) $127.87
- ZEPOSIA (Drug) $95.99
- XELJANZ (Drug) $92.87
- DIFICID (Drug) $54.72
- ENTYVIO (Biological) $50.13
- Bylvay (Drug) $39.94
- Qsymia (Drug) $39.50
- Humira (Biological) $39.28
- TRULANCE (Drug) $38.09
- INJECTAFER (Drug) $37.60
- SKYRIZI (Biological) $32.91
- INFLECTRA (Biological) $30.80
- SUCRAID (Drug) $28.12
- Mulpleta (Drug) $25.86
- MAVYRET (Drug) $23.15
- ZENPEP (Drug) $22.79
- IBSRELA (Drug) $22.29
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Gainesville
Charles Sninsky, Md, MD
Gastroenterology — Payments: $1.2M
Peter Draganov, Md, MD
Gastroenterology — Payments: $1.1M
Christopher Forsmark, Md, MD
Gastroenterology — Payments: $94,323
Ahmed Ouni
Gastroenterology — Payments: $31,897
Virginia Clark, Md, MD
Gastroenterology — Payments: $23,687
Dr. Roniel Cabrera, Md, MD
Gastroenterology — Payments: $22,274